Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancerMyrto Moutafi, David L. Rimm, Charles T. Robbins et al.|Laboratory Investigation|2022Cited by 141
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Cancer Research Communications|2023Cited by 19
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancerSaba Shafi, David L. Rimm, Thazin Nwe Aung et al.|Laboratory Investigation|2022Cited by 17
Supplementary Materials and Methods from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0
Supplementary Figure 4 from Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck CancerMyrto Moutafi, Amanda Psyrri, Georgia-Angeliki Koliou et al.|Unknown|2023Cited by 0